| Donafenib for Recurrent Cervical Cancer (NCT05310331) | Lei Li | 2022-03-27 |
| Tislelizumab and Radiotherapy for Recurrent Cervical Cancer (NCT05310383) | Lei Li | 2022-03-27 |
| PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer (NCT05310305) | Lei Li | 2022-03-26 |
| Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial (NCT05290935) | Lei Li | 2022-03-13 |
| Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma (NCT04664244) | Lei Li | 2020-12-19 |
| Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer (NCT04574635) | Mayo Clinic | 2020-11-17 |
| Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas (NCT04635956) | Lei Li | 2020-11-15 |
| Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy (NCT04188860) | Lei Li | 2019-12-06 |
| First-line Chemotherapy for Recurrent Cervical Cancer (NCT04188847) | Lei Li | 2019-12-06 |
| Paclitaxel Therapeutic Drug Monitoring in Cancer Patients (NCT03987555) | Wake Forest University Health Sciences | 2019-11-11 |
| Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers (NCT03968406) | M.D. Anderson Cancer Center | 2019-09-26 |
| SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer (NCT03816553) | Sun Yat-sen University | 2019-01-19 |
| DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers (NCT03439085) | M.D. Anderson Cancer Center | 2018-11-14 |
| Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer (NCT03277482) | Dana-Farber Cancer Institute | 2018-06-01 |
| Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers (NCT03345784) | National Cancer Institute (NCI) | 2018-05-29 |
| Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer (NCT02921269) | National Cancer Institute (NCI) | 2017-03-10 |
| the Re-irradiation of Recurrent Cervical Cancer by IMRT (NCT03170570) | Sun Yat-sen University | 2016-12-01 |
| Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations (NCT02646319) | Mayo Clinic | 2016-01-01 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCT02465060) | National Cancer Institute (NCI) | 2015-08-17 |
| Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer (NCT02257528) | National Cancer Institute (NCI) | 2015-05-18 |
| Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies (NCT02578888) | Albert Einstein College of Medicine | 2015-04-01 |
| MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer (NCT01992861) | University of Washington | 2014-02-14 |
| Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer (NCT01693783) | National Cancer Institute (NCI) | 2012-12-03 |
| Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer (NCT01266460) | Gynecologic Oncology Group | 2011-05-23 |
| Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer (NCT01267253) | Gynecologic Oncology Group | 2011-04-04 |
| Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer (NCT01281852) | National Cancer Institute (NCI) | 2011-03-14 |
| Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer (NCT01266447) | National Cancer Institute (NCI) | 2011-02-01 |
| Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer (NCT01098630) | Gynecologic Oncology Group | 2010-07-01 |
| Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery (NCT01026792) | National Cancer Institute (NCI) | 2009-12-01 |
| Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer (NCT00803062) | National Cancer Institute (NCI) | 2009-04-01 |
| Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer (NCT00499031) | Gynecologic Oncology Group | 2007-06-01 |
| ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer (NCT00309959) | Gynecologic Oncology Group | 2006-11-01 |
| Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix (NCT00064077) | Gynecologic Oncology Group | 2003-05-01 |
| Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer (NCT00057863) | National Cancer Institute (NCI) | 2003-01-01 |
| Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer (NCT00041093) | Gynecologic Oncology Group | 2002-06-01 |
| Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer (NCT00039442) | Gynecologic Oncology Group | 2002-04-29 |
| Collecting Tumor Samples From Patients With Gynecological Tumors (NCT00897442) | Gynecologic Oncology Group | 1992-06-01 |